1-3 of 3
Rupert Davies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study

Catherine Broome, David J Kuter, Keith R. McCrae, Rupert Davies, Amanda Enstrom, Allison Chunyk, Heather Thomas, Allison Naumovski, Steven R. Lentz
Journal: Blood
Blood (2023) 142 (Supplement 1): 5520.
https://doi.org/10.1182/blood-2023-179305
Published: 2023
Journal Articles

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Stacey R. Dillon, Rupert Davies, Jason D. Lickliter, Kristi L. Manjarrez, Alina Smith, Mary C. Lessig, Lori Blanchfield, Russell J. Sanderson, Allison Chunyk, Tiffany Blair, Amanda Enstrom, Hany Zayed, Stanford L. Peng
Journal: Blood
Blood (2022) 140 (Supplement 1): 8401–8403.
https://doi.org/10.1182/blood-2022-155908
Published: 2022
Journal Articles

ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity

Gordon Ng, PhD MSc, BSc, Thomas Spreter, PhD, Rupert Davies, PhD, Grant Wickman, PhD
Journal: Blood
Blood (2016) 128 (22): 1841.
https://doi.org/10.1182/blood.V128.22.1841.1841
Published: 2016